Miho Murata

Summary

Affiliation: National Institute of Neuroscience
Country: Japan

Publications

  1. ncbi Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study
    Miho Murata
    Department of Neurology, Musashi Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawahigashimachi, Kodaira, Tokyo 187 8551, Japan
    Neurology 68:45-50. 2007
  2. doi Levodopa in the early treatment of Parkinson's disease
    Miho Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry, Kodaira, Japan
    Parkinsonism Relat Disord 15:S17-20. 2009
  3. doi Zonisamide: a new drug for Parkinson's disease
    Miho Murata
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
    Drugs Today (Barc) 46:251-8. 2010
  4. doi LRRK2 P755L variant in sporadic Parkinson's disease
    Hiroyuki Tomiyama
    Department of Neurology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    J Hum Genet 53:1012-5. 2008
  5. ncbi Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group
    Shin Ichiro Ikebe
    Department of Neurology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo, Tokyo 113 8421, Japan
    Parkinsonism Relat Disord 9:S47-9. 2003
  6. doi Differential effects of fingolimod on B-cell populations in multiple sclerosis
    Masakazu Nakamura
    Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry NCNP, Tokyo, Japan Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Mult Scler 20:1371-80. 2014
  7. pmc Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study
    Manabu Araki
    From the Multiple Sclerosis Center M A, T O, S M, T A, T Y and Department of Neurology T O, M M, National Center Hospital, and Department of Immunology, National Institute of Neuroscience T M, S M, T A, T Y, National Center of Neurology and Psychiatry, Tokyo Department of Neurology K M, S K, Kinki University School of Medicine, Osaka and Department of Pediatrics T M, Graduate School of Medicine, University of Tokyo, Japan
    Neurology 82:1302-6. 2014
  8. ncbi [Severe kyphosis and esophagus hiatal hernia affected in the levodopa absorption of a patient with Parkinson's disease]
    Norio Chihara
    Department of Neurology, National Center Hospital of Neurology and Psychiatry
    Rinsho Shinkeigaku 49:493-6. 2009
  9. ncbi [Pharmacologic treatment of Parkinson disease]
    Miho Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry, 4 1 1 Ogawahigashi machi, Kodaira shi, Tokyo 187 8551, Japan
    Brain Nerve 61:464-72. 2009
  10. ncbi [Therapy of Parkinson's disease--up to date]
    Miho Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry
    Rinsho Shinkeigaku 48:986-8. 2008

Detail Information

Publications58

  1. ncbi Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study
    Miho Murata
    Department of Neurology, Musashi Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawahigashimachi, Kodaira, Tokyo 187 8551, Japan
    Neurology 68:45-50. 2007
    ..To evaluate the efficacy, safety and tolerability of daily doses of 25, 50, and 100 mg of zonisamide (ZNS) administered as adjunctive treatment in patients with Parkinson disease (PD)...
  2. doi Levodopa in the early treatment of Parkinson's disease
    Miho Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry, Kodaira, Japan
    Parkinsonism Relat Disord 15:S17-20. 2009
    ..Many investigations have shown that l-dopa does not accelerate disease progression. Now is the time to re-evaluate l-dopa for initial treatment of PD...
  3. doi Zonisamide: a new drug for Parkinson's disease
    Miho Murata
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
    Drugs Today (Barc) 46:251-8. 2010
    ....
  4. doi LRRK2 P755L variant in sporadic Parkinson's disease
    Hiroyuki Tomiyama
    Department of Neurology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    J Hum Genet 53:1012-5. 2008
    ..80, chi(2) = 0.064). No other variants were found in exon 19. Together with previous reports, our extended case-controlled study of large sample size suggests that LRRK2 P755L is a non-disease-associated polymorphism in PD patients...
  5. ncbi Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group
    Shin Ichiro Ikebe
    Department of Neurology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo, Tokyo 113 8421, Japan
    Parkinsonism Relat Disord 9:S47-9. 2003
    ..Rhabdomyolysis, disseminated intravascular coagulation, and acute renal failure constitute serious complications...
  6. doi Differential effects of fingolimod on B-cell populations in multiple sclerosis
    Masakazu Nakamura
    Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry NCNP, Tokyo, Japan Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Mult Scler 20:1371-80. 2014
    ....
  7. pmc Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study
    Manabu Araki
    From the Multiple Sclerosis Center M A, T O, S M, T A, T Y and Department of Neurology T O, M M, National Center Hospital, and Department of Immunology, National Institute of Neuroscience T M, S M, T A, T Y, National Center of Neurology and Psychiatry, Tokyo Department of Neurology K M, S K, Kinki University School of Medicine, Osaka and Department of Pediatrics T M, Graduate School of Medicine, University of Tokyo, Japan
    Neurology 82:1302-6. 2014
    ..To evaluate the safety and efficacy of a humanized anti-interleukin-6 receptor antibody, tocilizumab (TCZ), in patients with neuromyelitis optica (NMO)...
  8. ncbi [Severe kyphosis and esophagus hiatal hernia affected in the levodopa absorption of a patient with Parkinson's disease]
    Norio Chihara
    Department of Neurology, National Center Hospital of Neurology and Psychiatry
    Rinsho Shinkeigaku 49:493-6. 2009
    ..A single and a higher peak were observed for the plasma levodopa concentration, and the physical symptoms, including camptocormia and parkinsonism, were improved. Hunched posture could influence the absorption of antiparkinsonian drugs...
  9. ncbi [Pharmacologic treatment of Parkinson disease]
    Miho Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry, 4 1 1 Ogawahigashi machi, Kodaira shi, Tokyo 187 8551, Japan
    Brain Nerve 61:464-72. 2009
    ..Zonisamide may exert neuroprotective effects in parkinsonian patients...
  10. ncbi [Therapy of Parkinson's disease--up to date]
    Miho Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry
    Rinsho Shinkeigaku 48:986-8. 2008
    ..Base on the results of ELLDOPA study and "delayed start" clinical trials the most important concept for neuroprotection may be the early dopaminergic support for the degenerating dopaminergic system...
  11. doi GNE myopathy: a prospective natural history study of disease progression
    Madoka Mori-Yoshimura
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan Electronic address
    Neuromuscul Disord 24:380-6. 2014
    ..The 6-min walk test, gross motor function measure, manual muscle testing, grip power, and %FVC reflect annual changes and are thus considered good evaluation tools for clinical trials. ..
  12. doi Respiratory dysfunction in patients severely affected by GNE myopathy (distal myopathy with rimmed vacuoles)
    Madoka Mori-Yoshimura
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawahigashi, Kodaira, Tokyo 187 8551, Japan
    Neuromuscul Disord 23:84-8. 2013
    ..Respiratory dysfunction should be carefully monitored in patients with advanced GNE myopathy characterized by early onset and homozygous homozygous mutations in the N-acetylmannosamine kinase domain...
  13. doi Mutations for Gaucher disease confer high susceptibility to Parkinson disease
    Jun Mitsui
    Department of Neurology, University of Tokyo Graduate School of Medicine, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Arch Neurol 66:571-6. 2009
    ..Increased frequency of pathogenic variants in GBA, the causative gene for Gaucher disease, has been suggested to be associated with Parkinson disease (PD)...
  14. pmc Nationwide patient registry for GNE myopathy in Japan
    Madoka Mori-Yoshimura
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawahigashi, Kodaira 187 8551, Tokyo, Japan
    Orphanet J Rare Dis 9:150. 2014
    ....
  15. ncbi A collaborative study on the malignant syndrome in Parkinson's disease and related disorders
    Hideki Takubo
    Department of Neurology, Tokyo Rinkai Hospital, Tokyo, Japan
    Parkinsonism Relat Disord 9:S31-41. 2003
    ..Early introduction of treatment is important. Any elevation of body temperature during the course of anti-parkinsonian drug treatment should be considered as MS until proved otherwise...
  16. pmc Differential diagnosis tool for parkinsonian syndrome using multiple structural brain measures
    Miho Ota
    Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi, Kodaira, Tokyo 187 8502, Japan
    Comput Math Methods Med 2013:571289. 2013
    ..These findings support the view that each parkinsonian syndrome has structural deviations in multiple brain areas and that a combination of structural brain measures can help to distinguish parkinsonian syndromes...
  17. doi Diffusion tensor tract-specific analysis of the uncinate fasciculus in patients with progressive supranuclear palsy
    Kouhei Kamiya
    Department of Radiology, National Center Hospital of Neurology and Psychiatry, 4 1 1 Ogawahigashi chyo, Kodaira, Tokyo 187 8551, Japan
    J Neuroradiol 40:121-9. 2013
    ..This retrospective study aimed to evaluate damage to the UF and ILF in patients with progressive supranuclear palsy (PSP) using diffusion tensor tract-specific analysis...
  18. pmc Tailor-made RNAi knockdown against triplet repeat disease-causing alleles
    Masaki Takahashi
    National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187 8502, Japan
    Proc Natl Acad Sci U S A 107:21731-6. 2010
    ....
  19. doi Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study
    Yoshikuni Mizuno
    Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan Electronic address
    Parkinsonism Relat Disord 20:1388-93. 2014
    ..To confirm the superiority of transdermal rotigotine up to 16 mg/24 h over placebo, and non-inferiority to ropinirole, in Japanese Parkinson's disease (PD) patients on concomitant levodopa therapy...
  20. ncbi [Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy]
    Kensuke Ikeda
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry
    Rinsho Shinkeigaku 53:19-23. 2013
    ..We should pay attention to nephrotic syndrome under using long-term IFNβ...
  21. pmc Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica
    Norio Chihara
    Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry NCNP, Tokyo, Japan Department of Neurology, Kobe University Graduate School of Medicine, Kobe, Japan
    PLoS ONE 8:e83036. 2013
    ..Since migratory plasmablasts could be involved in the inflammatory pathology of NMO, the B-cell subset and their migration might be an attractive therapeutic target. ..
  22. doi Videofluorographic detection of anti-muscle-specific kinase-positive myasthenia gravis
    Toshiyuki Yamamoto
    Department of Neurology, National Center Hospital of Neurology and Psychiatry, Tokyo, Japan
    Am J Otolaryngol 33:758-61. 2012
    ..Thus VF during EC test may be helpful in diagnosing MuSK-MG in patients with dysphagia...
  23. doi Long-term effect of repeated lidocaine injections into the external oblique for upper camptocormia in Parkinson's disease
    Yoshihiko Furusawa
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi cho, Kodaira, Tokyo 187 8551, Japan
    Parkinsonism Relat Disord 19:350-4. 2013
    ..The effect of a single lidocaine injection disappeared over a period of few days. In this study, we used repeated lidocaine injections into the external oblique for 4-5 days and evaluated the effects of such treatment for up to 90 days...
  24. ncbi New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C
    Tomoya Kawazoe
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan
    Intern Med 51:2625-9. 2012
    ..Patients undergoing type 1 interferon therapy should therefore be carefully monitored for any manifestations of autoimmune diseases...
  25. ncbi [Discovery of an antiparkinsonian drug: zonisamide]
    Miho Murata
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry
    Rinsho Shinkeigaku 50:780-2. 2010
    ....
  26. pmc CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis
    Wakiro Sato
    Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187 8502, Japan
    J Immunol 189:5057-65. 2012
    ..0005) and expressed higher levels of IFN-γ and matrix metalloproteinase-9. Taken together, we propose that autoimmune CCR2(+)CCR5(+)CCR6(-) Th1 cells play a crucial role in the pathogenesis of MS...
  27. doi Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study
    Yoshihiko Furusawa
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawahigashi cho, Kodaira, Tokyo, 187 8551, Japan
    J Inherit Metab Dis 35:301-10. 2012
    ..These results suggest that ERT continues to be effective in the second year of treatment even in patients suffering from advanced late-onset GSDII disease with severe respiratory failure...
  28. ncbi [Patients' perspective on Parkinson disease therapies: results of a large-scale survey in Japan]
    Ken ichi Fujimoto
    Department of Neurology, Jichi Medical University, Japan
    Brain Nerve 63:255-65. 2011
    ..Hallucination is the most distressing side effect. For patients preferring mobility over dyskinesia, levodopa should be dosed sufficiently, and possibly titrated, to maximize clinical benefit and patient satisfaction...
  29. pmc Mutant huntingtin impairs Ku70-mediated DNA repair
    Yasushi Enokido
    Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo ku, Tokyo, Japan
    J Cell Biol 189:425-43. 2010
    ..Expression of exogenous Ku70 rescues abnormal behavior and pathological phenotypes in the R6/2 mouse model of Huntington's disease (HD). These results collectively suggest that Ku70 is a critical regulator of DNA damage in HD pathology...
  30. ncbi Diffusion tensor imaging in familial spastic paraplegia with mental impairment and thin corpus callosum
    Miho Ota
    Department of Radiology, National Center Hospital for Mental, Nervous and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo, Japan
    Magn Reson Med Sci 7:163-7. 2008
    ..DTI and SPECT effectively revealed global changes not revealed by conventional MR imaging...
  31. ncbi [Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy]
    Atsuko Nishikawa
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry
    Rinsho Shinkeigaku 54:561-4. 2014
    ..Her symptoms worsened with ambenonium chloride but improved with 3,4-diaminopyridine. Our findings suggest that daily or weekly fluctuation and worsening with a menses in muscle weakness is an important diagnostic feature of CMS. ..
  32. ncbi Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population
    Manabu Funayama
    Research Institute for Diseases of Old Age, Department of Neurology, Juntendo University School of Medicine, Bunkyo ku, Tokyo, and Department of Neurology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
    Neuroreport 18:273-5. 2007
    ..24x10(-4), odds ratio 2.63, 95% confidence interval 1.56-4.35). Our results suggest that the G2385R variant is a risk factor for sporadic Parkinson disease in the Asian population...
  33. doi Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2
    Madoka Mori-Yoshimura
    Department of Neurology, National Center Hospital of Neurology and Psychiatry, 4 1 1 Ogawahigashi cho, Kodaira, Tokyo 187 8551, Japan
    Clin Neurol Neurosurg 114:678-83. 2012
    ..Missense mutations in dynamin 2 gene (DNM2) are associated with autosomal dominant centronuclear myopathy (CNM) with characteristic histopathological findings of centrally located myonuclei in a large number of muscle fibers...
  34. doi Validation of the Japanese translation of the Swallowing Disturbance Questionnaire in Parkinson's disease patients
    Toshiyuki Yamamoto
    Department of Neurology, National Center Hospital of Neurology and Psychiatry, Kodaira, Tokyo 187 8551, Japan
    Qual Life Res 21:1299-303. 2012
    ..We developed the Japanese version of this questionnaire (SDQ-J), according to the cross-cultural adaptation guidelines, and examined its reliability...
  35. ncbi [The discovery of an antiparkinsonian drug, zonisamide]
    Miho Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry
    Rinsho Shinkeigaku 50:67-73. 2010
    ..We will verify the neuroprotective effects of ZNS on patients with Parkinson disease and study the factors responsible for the individual difference of the effects of ZNS by using genome wide association study (GWAS) in the near feature...
  36. pmc p62 plays a protective role in the autophagic degradation of polyglutamine protein oligomers in polyglutamine disease model flies
    Yuji Saitoh
    From the Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi, Kodaira, Tokyo 187 8502, Japan, The Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi, Kodaira, Tokyo 187 8551, Japan, the Graduate School of Medical and Pharmaceutical Sciences, Chiba University, 1 8 1, Inohana, Chuo Ku, Chiba, Chiba 260 8670, Japan
    J Biol Chem 290:1442-53. 2015
    ....
  37. doi Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses
    Hiroyuki Ishiura
    Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    J Hum Genet 59:163-72. 2014
    ..1% (7/63) of them. The present study elucidated the molecular epidemiology of HSP in the Japanese population and further broadened the mutational and clinical spectra of HSP. ..
  38. doi Heterozygous UDP-GlcNAc 2-epimerase and N-acetylmannosamine kinase domain mutations in the GNE gene result in a less severe GNE myopathy phenotype compared to homozygous N-acetylmannosamine kinase domain mutations
    Madoka Mori-Yoshimura
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, 4 1 1 Ogawahigashi, Kodaira, Tokyo 187 8551, Japan
    J Neurol Sci 318:100-5. 2012
    ..Here, we examined the relationship between genotype and clinical phenotype in participants with GNE myopathy...
  39. pmc Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys
    Nobutaka Hattori
    Department of Neurology, Juntendo University School of Medicine, Tokyo
    Patient Relat Outcome Meas 3:31-8. 2012
    ..These two surveys, based in Japan and the US, investigated the attitudes of patients towards antiparkinsonian medications, the complications of these therapies, and how these differ across geographies...
  40. ncbi [Treatment of subcutaneous and mediastinal emphysema with cuirass ventilation in a patient with Pompe disease undergoing non-invasive positive pressure ventilation]
    Yoshihiko Furusawa
    Department of Neurology, National Center Hospital of Neurology and Psychiatry
    Rinsho Shinkeigaku 50:306-10. 2010
    ..Thus, a combination of cuirass ventilation and NPPV is beneficial in managing barotrauma that may occur during NPPV in a respirator-dependent patient...
  41. ncbi [The therapy of wearing-off]
    Miho Murata
    Department of Neurology, Musashi Hospital, National Center of Neurology and Psychiatry
    Nihon Rinsho 62:1716-9. 2004
    ....
  42. ncbi [Depression in Parkinson's disease]
    Miho Murata
    Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry
    Nihon Ronen Igakkai Zasshi 50:752-4. 2013
    ..Antiparkinsonian drugs may have beneficial effects not only on the motor symptoms of the disease, but also the patient's mood. Cognitive behavioral therapy (CBT) and peer counseling may also be beneficial. ..
  43. ncbi [A guideline for the treatment of Parkinson's disease]
    Yoshikuni Miziuno
    Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
    Rinsho Shinkeigaku 42:421-94. 2002
  44. ncbi Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein
    Masataka Hoshino
    Department of Molecular Therapeutics, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan
    J Neurochem 87:257-67. 2003
    ..Collectively, retained activity in affected neurons supports application of anti-HDAC drugs to the therapy of HD...
  45. pmc Treatment of neuromyelitis optica: current debate
    Tomoko Okamoto
    Department of Neurology, Musashi Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
    Ther Adv Neurol Disord 1:5-12. 2008
    ..An emerging idea that pathogenesis of NMO may involve an interaction of the newly identified helper T cell subset, Th17, with B cells offers potential targets of therapy...
  46. ncbi [Monthly low-dose immunoglobulin infusion as a maintenance therapy for multifocal motor neuropathy may reduce allergic adverse effects: a case report]
    Yoshiko Murata
    Department of Neurology, National Center Hospital of Neurology and Psychiatry
    Rinsho Shinkeigaku 50:561-5. 2010
    ..4 g/kg for one day) once every month. After more than 8 months of low-dose therapy, only mild form of pompholyx remained and the muscle strength was maintained without further deterioration...
  47. doi Risk of pneumonia onset and discontinuation of oral intake following videofluorography in patients with Lewy body disease
    Toshiyuki Yamamoto
    Department of Rehabilitation, National Center Hospital of Neurology and Psychiatry, 4 1 1 Ogawahigashi cho, Kodaira City, Tokyo 187 8551, Japan
    Parkinsonism Relat Disord 16:503-6. 2010
    ..We investigated the time course of pneumonia onset and duration of continued oral intake following videofluorography (VFG) in patients with Lewy body disease...
  48. doi Degeneration of dementia with Lewy bodies measured by diffusion tensor imaging
    Miho Ota
    Department of Radiology, Musashi Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan
    NMR Biomed 22:280-4. 2009
    ..Our results showed degeneration of the ILF, which is responsible for visuospatial cognition. ILF dysfunction may influence the clinical features in DLB...
  49. ncbi Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease
    Kenya Nishioka
    Department of Neurology, Juntendo University School of Medicine, Hongo, Tokyo, Japan
    Ann Neurol 59:298-309. 2006
    ..The objective of this study was to assess the frequency of SNCA multiplications among autosomal dominant hereditary Parkinson's disease (ADPD)...
  50. ncbi Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation
    Masato Asanuma
    Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikatacho, Okayama 700 8558, Japan
    Neurosci Res 60:106-13. 2008
    ..Our results suggest that the novel anti-parkinsonian agent ZNS possesses preventing effects against DA quinone formation induced by excess amount of cytosolic DA outside the synaptic vesicles...
  51. ncbi [Therapy for patients with progressive Parkinson's disease]
    Miho Murata
    Nihon Naika Gakkai Zasshi 92:1432-7. 2003
  52. ncbi Toward identification of susceptibility genes for sporadic Parkinson's disease
    Tatsushi Toda
    Division of Functional Genomics, Department of Post Genomics and Diseases, Osaka University Graduate School of Medicine, 2 2 B9 Yamadaoka, Suita, 565 0871, Osaka, Japan
    J Neurol 250:III40-3. 2003
    ..9 x 10(-6)) on chromosome 1 where other studies showed a linkage. Genes in linkage disequilibrium with these markers may be associated with pathogenesis of PD...
  53. doi Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease
    Ikuko Mizuta
    Division of Clinical Genetics, Department of Medical Genetics, Osaka University Graduate School of Medicine, 2 2 B9 Yamadaoka, Suita, Osaka, 565 0871, Japan
    Hum Genet 124:89-94. 2008
    ..Our genetic analysis suggests that CALB1 is associated with PD independently of SNCA, and that FGF20 is associated with PD synergistically with SNCA...
  54. ncbi Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms
    Yoshio Momose
    Division of Functional Genomics, Department of Post Genomics and Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
    Ann Neurol 51:133-6. 2002
    ..46) and confirmed an association with the S18Y polymorphism of the UCH-L1 gene. Our results provide genetic evidence supporting a role for BDNF in the pathogenesis of Parkinson's disease...
  55. ncbi [The development of therapeutic agents for Parkinson's disease and problems in their clinical application]
    Miho Murata
    Nihon Yakurigaku Zasshi 131:281-4. 2008
  56. ncbi Session 3 "Analyzer Workshop" evolution of therapeutic strategies in Parkinson's disease
    Nobuo Yanagisawa
    Kanto Rosai Hospital
    J Neurol 251:vII24-30. 2004
  57. ncbi Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease
    Ikuko Mizuta
    Division of Clinical Genetics, Department of Medical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan
    Hum Mol Genet 15:1151-8. 2006
    ..SNCA expression levels tended to be positively correlated with the number of the associated allele in autopsied frontal cortices. These findings establish SNCA as a definite susceptibility gene for sporadic PD...
  58. ncbi Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population
    Wataru Satake
    Division of Clinical Genetics, Department of Medical Genetics, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka, Japan
    Neuroreport 18:937-40. 2007
    ..0075). These results suggest that the FGF20 gene is a susceptibility gene for Parkinson's disease in the Japanese population...